Format

Send to

Choose Destination
Chest. 2014 Nov;146(5):1358-1368. doi: 10.1378/chest.14-0917.

Diagnosis and treatment of pulmonary aspergillosis syndromes.

Author information

1
From the The Pulmonary, Allergy and Critical Care Division, University of Pennsylvania, Pennsylvania, PA. Electronic address: karen.patterson@uphs.upenn.edu.
2
The Section of Pulmonary and Critical Care, University of Chicago, Chicago, IL.

Abstract

Both inherited and acquired immunodeficiency and chronic pulmonary disease predispose to the development of a variety of pulmonary syndromes in response to Aspergillus, a fungus that is ubiquitous in the environment. These syndromes include invasive aspergillosis, which is now recognized to occur in patients with critical illness without neutropenia and in those with mild degrees of immunosuppression, including from corticosteroid use in the setting of COPD. Chronic pulmonary aspergillosis includes simple aspergilloma, which is occasionally complicated by life-threatening hemoptysis, and progressive destructive cavitary disease requiring antifungal therapy. Allergic bronchopulmonary aspergillosis occurs almost exclusively in patients with asthma or cystic fibrosis. Recent advances in each of these syndromes include a greater understanding of the underlying pathophysiology and hosts at risk; improved diagnostic algorithms; and the availability of more effective and well-tolerated therapies. Improvement in outcomes for Aspergillus pulmonary syndromes requires that physicians recognize the varied and sometimes subtle presentations, be aware of populations at risk of illness, and institute potentially life-saving therapies early in the disease course.

PMID:
25367472
DOI:
10.1378/chest.14-0917
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center